Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight
The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the same time, a robust pipeline of therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis/MorphoSys), Cenerimod (Idorsia Pharmaceuticals/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), and others is expected to further transform disease management.
New York, USA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight
The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the same time, a robust pipeline of therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis/MorphoSys), Cenerimod (Idorsia Pharmaceuticals/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), and others is expected to further transform disease management.
Recently published Lupus Nephritis Market Insights report includes a comprehensive understanding of current treatment practices, lupus nephritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Lupus Nephritis Market Summary
- The market size for lupus nephritis was found to be USD 2.1 billion in the 7MM in 2025.
- The United States accounted for the largest lupus nephritis treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- The total diagnosed prevalent cases of lupus nephritis in the 7MM were 375,800 in 2025, and this number is projected to increase by 2036.
- Key lupus nephritis companies, including AstraZeneca, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, Autolus, AbelZeta, Cabaletta Bio, Fate Therapeutics, and others, are actively working on innovative lupus nephritis drugs.
- Some of the key lupus nephritis therapies in clinical trials include Anifrolumab (SAPHNELO), Ianalumab (VAY736), Cenerimod, Rapcabtagene autoleucel (YTB323), Iptacopan (FABHALTA), Obecabtagene autoleucel (obe-cel), C-CAR168, Resecabtagene autoleucel (CABA-201), FT819, and others. These novel lupus nephritis therapies are anticipated to enter the lupus nephritis market in the forecast period and are expected to change the market.
Discover more about lupus nephritis prevalence statistics @ https://www.delveinsight.com/report-store/lupus-nephritis-market
Key Factors Driving the Growth of the Lupus Nephritis Market
- Increasing Prevalence of Systemic Lupus Erythematosus: The growing prevalence of systemic lupus erythematosus (SLE), a significant proportion of whom develop lupus nephritis, is expanding the patient population requiring treatment. Improved disease recognition and diagnosis are also contributing to greater identification of eligible patients.
- Growing Demand for Targeted and Effective Therapies: The limitations and safety concerns associated with conventional immunosuppressive treatments have created a need for more targeted therapies. Novel biologics and other advanced treatment approaches are helping address unmet needs in patients with active or difficult-to-manage disease.
- Advancements in the Clinical Pipeline: A robust pipeline of investigational therapies, including Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis/MorphoSys), Cenerimod (Idorsia Pharmaceuticals/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), Iptacopan (FABHALTA; Novartis), and others with diverse mechanisms of action, is expected to reshape the lupus nephritis treatment landscape. Ongoing clinical trials and positive study outcomes could introduce new treatment options and intensify market competition.
- Growing Interest in CAR-T Therapy for Lupus Nephritis: The success of CAR-T therapies in oncology has accelerated interest in their application to autoimmune diseases, including lupus nephritis. Early clinical evidence demonstrating deep B-cell depletion and potential long-term disease control has attracted substantial investment, positioning CAR-T therapy as a promising future disease-modifying approach.
- Rising Focus on Personalized Treatment Approaches: The heterogeneity of lupus nephritis is driving interest in personalized and targeted treatment strategies. Advances in biomarkers and disease monitoring may help optimize therapy selection and improve long-term patient outcomes.
Aparna Thakur, project manager of forecasting at DelveInsight, said that all CAR-T therapies, C-CAR168, resecabtagene autoleucel, and rapcabtagene autoleucel, obecabtagene autoleucel show promise for treating lupus nephritis, but it is too early to definitively say which is better.
Lupus Nephritis Market Analysis
- At present, three therapies have received FDA approval for the treatment of lupus nephritis: belimumab (BENLYSTA), approved in 2020 and subsequently extended to pediatric patients in 2022; voclosporin (LUPKYNIS), approved in 2021 as the first oral therapy specifically indicated for lupus nephritis; and obinutuzumab (GAZYVA/GAZYVARO), approved in 2025, broadening the range of biologic treatment options available for patients with active disease.
- Despite these advances, the existing standard of care for lupus nephritis continues to rely largely on broad-spectrum immunosuppressive agents, which are associated with considerable short- and long-term toxicity.
- Growing research efforts have focused on developing targeted therapies designed to modulate specific inflammatory and immune pathways implicated in disease progression.
- The lupus nephritis market has also attracted increasing interest from major pharmaceutical companies.
- The evolving drug pipeline includes several innovative therapeutic approaches, such as complement inhibitors like iptacopan, BAFF-R antagonists such as ianalumab, monoclonal antibodies including anifrolumab, sphingosine-1-phosphate 1 receptor modulators such as cenerimod, and CAR-T therapies including resecabtagene autoleucel, rapcabtagene autoleucel, obecabtagene autoleucel, C-CAR168, and mivocabtagene autoleucel.
- These emerging therapies are anticipated to contribute to significant changes in the lupus nephritis treatment landscape through 2036, potentially enabling more targeted, personalized, and effective disease management.
Learn more about lupus and lupus nephritis clinical trials disease mechanism alignment @ Lupus Nephritis Treatment Market
Lupus Nephritis Competitive Landscape
Some of the lupus nephritis drugs under development include Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis/MorphoSys), Cenerimod (Idorsia Pharmaceuticals/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), Iptacopan (FABHALTA; Novartis), Obecabtagene autoleucel (obe-cel; Autolus), C-CAR168 (AbelZeta), Resecabtagene autoleucel (CABA-201; Cabaletta Bio), FT819 (Fate Therapeutics), and others.
AstraZeneca’s SAPHNELO (anifrolumab) is an intravenous, fully human monoclonal antibody that targets Subunit 1 of the Type I interferon (IFN) receptor. By binding to this receptor, the therapy inhibits Type I IFN signaling. Type I IFNs, including IFN-alpha, IFN-beta, and IFN-kappa, are cytokines that play an important role in the regulation of inflammatory responses.
AstraZeneca is currently assessing SAPHNELO in the Phase III IRIS trial (NCT05138133) for adults with active proliferative lupus nephritis. According to the company’s 2024 full-year results update, topline results from the Phase III IRIS study are expected in 2026.
Fate Therapeutics’ FT819 is an allogeneic, off-the-shelf CD19-directed CAR T-cell therapy candidate designed to enhance both safety and therapeutic efficacy. Fate Therapeutics has initiated the Phase II RECLAIM-LN study and treated its first patient to evaluate FT819 in individuals with moderate-to-severe systemic lupus erythematosus (SLE) accompanied by Class III or IV lupus nephritis.
The open-label trial is expected to enroll approximately 53 patients and will evaluate the safety and efficacy of a single 900-million-cell dose of FT819. The primary endpoint is the percentage of patients achieving a complete renal response at Week 26. The study incorporates recommendations provided by the US FDA as part of FT819’s Regenerative Medicine Advanced Therapy (RMAT) designation.
Novartis’ Rapcabtagene autoleucel is an investigational autologous CD19-directed CAR T-cell therapy developed on Novartis’s T-Charge platform. The treatment uses a patient’s own T cells, which are genetically modified to express a CD19-specific chimeric antigen receptor (CAR), allowing selective targeting and depletion of B cells involved in autoimmune disease. Delivered as a single intravenous infusion, rapcabtagene autoleucel is intended to achieve profound and durable B-cell depletion.
Novartis is currently investigating rapcabtagene autoleucel in a Phase II clinical study for SLE and lupus nephritis. Based on Novartis’s 2026 interim financial report, the company expects to submit regulatory applications for rapcabtagene autoleucel in lupus nephritis/SLE in 2028.
The anticipated launch of these emerging lupus nephritis therapies are poised to transform the lupus nephritis market landscape in the coming years. As these cutting-edge lupus nephritis therapies continue to mature and gain regulatory approval, they are expected to reshape the lupus nephritis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about lupus nephritis treatment options, visit @ Lupus Nephritis Drugs
Recent Developments in the Lupus Nephritis Market
- In August 2026, Fate Therapeutics initiated a potentially registrational RECLAIM-LN clinical trial for the treatment of lupus nephritis
- In July 2026, AbelZeta Pharma announced that the U.S. FDA has granted clearance under its Regenerative Medicine Advanced Therapy (RMAT) designation for a multicenter, registrational Phase II clinical trial of C-CAR168, an anti-CD20/BCMA bispecific CAR-T therapy, in patients with lupus nephritis who are refractory to standard treatment.
- In July 2026, AbelZeta Pharma announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted PRIority MEdicines (PRIME) designation to C-CAR168, the company’s novel autologous anti-CD20/BCMA CAR-T cell therapy, for the treatment of refractory systemic lupus erythematosus (SLE), including patients with or without lupus nephritis (LN).
- In July 2026, Aurinia Pharmaceuticals Inc. announced the launch of PRESERVE, a Phase IV, multicenter study evaluating LUPKYNIS® in combination with belimumab, obinutuzumab, or anifrolumab in patients with lupus nephritis. The study is expected to enroll approximately 150 patients across around 50 sites in the United States, with the primary endpoint assessing the proportion of patients who achieve complete renal response (CRR) at 6 months.
Lupus Nephritis Epidemiology Segmentation
The lupus nephritis epidemiology section provides insights into the historical and current Lupus Nephritis patient pool and forecasted trends for the leading markets. US contributed the largest prevalent population of Lupus nephritis, accounting for ~57% of the 7MM in 2025. These cases are anticipated to increase in the upcoming years.
The lupus nephritis market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
- Total Diagnosed Prevalent Cases of Lupus Nephritis
- Age-specific Diagnosed Prevalent Cases of Lupus Nephritis
- Diagnosed Prevalent Cases of Lupus Nephritis by Class
- Total Treated Cases of Lupus Nephritis
Download the report to understand the future of lupus nephritis treatment @ Treatment for Lupus Nephritis
| Lupus Nephritis Market Report Metrics | Details |
| Study Period | 2022–2036 |
| Lupus Nephritis Market Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Lupus Nephritis Market CAGR (2022–2036) | 7% |
| Lupus Nephritis Market Size in 2025 | USD 2.1 Billion |
| Key Lupus Nephritis Companies | AstraZeneca, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, Autolus, AbelZeta, Cabaletta Bio, Fate Therapeutics, GlaxoSmithKline, Aurinia Pharmaceuticals, Otsuka Pharmaceuticals, Roche, and others |
| Key Lupus Nephritis Therapies | Anifrolumab (SAPHNELO), Ianalumab (VAY736), Cenerimod, Rapcabtagene autoleucel (YTB323), Iptacopan (FABHALTA), Obecabtagene autoleucel (obe-cel), C-CAR168, Resecabtagene autoleucel (CABA-201), FT819, BENLYSTA, LUPKYNIS, GAZYVA/GAZYVARO, and others |
Scope of the Lupus Nephritis Market Report
- Lupus Nephritis Patient Population Forecast
- Lupus Nephritis Therapeutics Market Size
- Lupus Nephritis Pipeline Analysis
- Lupus Nephritis Market Size and Trends
- Lupus Nephritis Market Opportunity
- Lupus Nephritis Market Unmet Needs
- KOL’s Views on Lupus Nephritis
- Lupus Nephritis Market Access and Reimbursement
Discover more about next-generation lupus nephritis drugs @ Lupus Nephritis Clinical Trials
Table of Contents
| 1 | Lupus Nephritis Market Key Insights |
| 2 | Lupus Nephritis Market Report Introduction |
| 3 | Executive Summary of Lupus Nephritis |
| 4 | Key Events |
| 5 | Epidemiology and Market Forecast Methodology |
| 6 | Lupus Nephritis Market Overview at a Glance |
| 6.1 | Clinical Landscape Analysis (By Phase, RoA, and Molecule Type) |
| 6.2 | Market Share (%) Distribution of Lupus Nephritis by Therapy in 2025 |
| 6.3 | Market Share (%) Distribution of Lupus Nephritis by Therapy in 2036 |
| 7 | Disease Background and Overview of Lupus Nephritis |
| 7.1 | Introduction |
| 7.2 | Types of Lupus |
| 7.3 | Causes and Risk Factors |
| 7.4 | Signs and Symptoms of Lupus Nephritis |
| 7.5 | Classification of Lupus Nephritis |
| 7.6 | Pathophysiology of Lupus Nephritis |
| 7.7 | Biomarkers of Lupus Nephritis |
| 7.8 | Complications of Lupus Nephritis |
| 7.9 | Diagnosis |
| 7.10 | Diagnosis Algorithm |
| 7.11 | Differential Diagnosis |
| 8 | Treatment of Lupus Nephritis |
| 8.1 | Classes III and IV Induction Therapy |
| 8.2 | Class V Induction Therapy |
| 8.3 | Treatment Options for Kidney Failure |
| 8.4 | Treatment Algorithm |
| 8.5 | Guidelines of Lupus Nephritis |
| 9 | Epidemiology and Patient Population of Lupus Nephritis |
| 9.1 | Key Findings |
| 9.2 | Assumptions and Rationale |
| 9.3 | Total Diagnosed Prevalent Cases of SLE in the 7MM |
| 9.4 | Total Diagnosed Prevalent Cases of Lupus Nephritis in the 7MM |
| 9.5 | Total Treated Cases of Lupus Nephritis in the 7MM |
| 9.6 | The United States |
| 9.6.1 | Total Diagnosed Prevalent Cases of Lupus Nephritis in the United States |
| 9.6.2 | Age-specific Diagnosed Prevalent Cases of Lupus Nephritis in the United States |
| 9.6.3 | Diagnosed Prevalent Cases of Lupus Nephritis by Class in the United States |
| 9.6.4 | Total Treated Cases of Lupus Nephritis in the United States |
| 9.7 | EU4 and the UK |
| 9.8 | Japan |
| 10 | Patient Journey of Lupus Nephritis |
| 11 | Marketed Therapies |
| 11.1 | Marketed Competitive Landscape |
| 11.2 | Voclosporin (LUPKYNIS): Aurinia Pharmaceuticals/Otsuka Pharmaceuticals |
| 11.2.1 | Drug Description |
| 11.2.2 | Regulatory Milestones |
| 11.2.3 | Other Developmental Activities |
| 11.2.4 | Summary of Pivotal Trials |
| 11.2.5 | Clinical Development |
| 11.2.5.1 | Clinical Trial Information |
| 11.2.6 | Safety and Efficacy |
| 11.2.7 | Analyst Views |
| 11.3 | Belimumab (BENLYSTA): GlaxoSmithKline |
| 12 | Emerging Lupus Nephritis Drugs |
| 12.1 | Emerging Competitive Landscape |
| 12.2 | Anifrolumab (SAPHNELO): AstraZeneca |
| 12.2.1 | Product Description |
| 12.2.2 | Other Development Activities |
| 12.2.3 | Clinical Development |
| 12.2.3.1 | Clinical Trial Information |
| 12.2.4 | Safety and Efficacy |
| 12.2.5 | Analyst Views |
| 12.3 | Ianalumab (VAY736): Novartis |
| 12.4 | Iptacopan (FABHALTA): Novartis |
| 12.5 | Rapcabtagene autoleucel (YTB323): Novartis |
| 12.6 | Resecabtagene autoleucel (CABA-201): Cabaletta Bio |
| 12.7 | C-CAR168: AbelZeta |
| List to be continued in the final report | |
| 13 | Lupus Nephritis Market: 7MM Analysis |
| 13.1 | Key Findings |
| 13.2 | Lupus Nephritis Market Outlook |
| 13.3 | Conjoint Analysis |
| 13.4 | Key Lupus Nephritis Market Forecast Assumptions |
| 13.4. | Launch Year and Therapy Uptakes |
| 13.5 | Total Market Size of Lupus Nephritis in the 7MM |
| 13.6 | Market Size of Lupus Nephritis by Therapies in 7MM |
| 13.7 | United States Lupus Nephritis Market Size |
| 13.7.1 | Total Market Size of Lupus Nephritis in the United States |
| 13.7.2 | Market Size of Lupus Nephritis by Therapies in the United States |
| 13.8 | EU4 and UK Lupus Nephritis Market Size |
| 13.9 | Japan Lupus Nephritis Market Size |
| 14 | Unmet Needs of Lupus Nephritis |
| 15 | SWOT Analysis of Lupus Nephritis |
| 16 | KOL Views of Lupus Nephritis |
| 17 | Market Access and Reimbursement of Lupus Nephritis Therapies |
| 17.1 | The US |
| 17.2 | In EU4 and the UK |
| 17.3 | Japan |
| 17.4 | Summary and Comparison of Market Access and Pricing Policy Developments in 2025 |
| 17.5 | Market Access and Reimbursement of Alport syndrome Therapies |
| 18 | Bibliography |
| 19 | Lupus Nephritis Market Report Methodology |
Related Reports
Lupus Nephritis Clinical Trial Analysis
Lupus Nephritis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key lupus nephritis companies, including Novartis, Simcere Pharmaceutical Co., Ltd, Nanjing Immunophage Biotech Co., Ltd, Kyverna Therapeutics, Century Therapeutics, Adicet Bio, Resolve Therapeutics, Dragonfly Therapeutics, Kite, A Gilead Company, Regeneron Pharmaceuticals Inc., and others.
Systemic Lupus Erythematosus Market
Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SLE companies including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, and others.
Systemic Lupus Erythematosus Clinical Trial Analysis
Systemic Lupus Erythematosus Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key SLE companies, including Roche, Biogen, Viatris Inc., Novartis, Qilu Pharmaceutical, ImmuPharma, Beijing Mabworks Biotech Co., Ltd., Zenas Biopharma, AbbVie, Beijing InnoCare Pharma Tech Co., Ltd., Alumis Inc., Galapagos NV, Palleon Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Johnson & Johnson, Merck KGaA, Resolve Therapeutics, ILTOO Pharma, Argenx, Cartesian Therapeutics, Keymed Biosciences Co., Ltd, BioSenic, Eisai, Vertex Pharmaceuticals, Kyverna Therapeutics, Miltenyi Biomedicine, Astrazeneca, Otsuka Pharmaceutical, Fresh Tracks Therapeutics, Nucleome Therapeutics, OMass Therapeutics, and others.
IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key IgAN companies including Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, and others.
IgA Nephropathy Clinical Trial Analysis
IgA Nephropathy Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key IgAN companies, including Novartis Pharmaceuticals, Biohaven, Ltd., Keymed Biosciences Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., ADARx Pharmaceuticals Inc., Biogen, Suzhou Rigerna Therapeutics, Wuxi BioCity Biopharmaceutics Co., Ltd., Transcenta Holding, Climb Bio, Chengdu Suncadia Medicine Co., Ltd., Purespring Therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
